231 related articles for article (PubMed ID: 28532857)
1. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
Reyes HD; Miecznikowski J; Gonzalez-Bosquet J; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Stephan JM; Hanjani P; Guntupalli S; Tewari KS; Backes F; Ramirez N; Fleming GF; Filiaci V; Birrer MJ; Leslie KK
Gynecol Oncol; 2017 Aug; 146(2):247-253. PubMed ID: 28532857
[TBL] [Abstract][Full Text] [Related]
2. The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.
Spirtos NM; Enserro D; Homesley HD; Gibbons SK; Cella D; Morris RT; DeGeest K; Lee RB; Miller DS
Gynecol Oncol; 2019 Jul; 154(1):13-21. PubMed ID: 31053405
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Walker JL; Moore KN; Waggoner SE; Thaker PH; Rizack T; Hoffman JS; Fracasso PM
Gynecol Oncol; 2015 Jul; 138(1):36-40. PubMed ID: 25958319
[TBL] [Abstract][Full Text] [Related]
4. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.
Trovik J; Wik E; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; Njolstad TS; ; Vandenput I; Amant F; Akslen LA; Salvesen HB
Clin Cancer Res; 2011 May; 17(10):3368-77. PubMed ID: 21242118
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
[TBL] [Abstract][Full Text] [Related]
6. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
7. Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
Sueoka K; Umayahara K; Abe A; Usami T; Yamamoto A; Nomura H; Matoda M; Okamoto S; Omatsu K; Kondo E; Kato K; Takeshima N
Int J Gynecol Cancer; 2015 Jan; 25(1):81-6. PubMed ID: 25347094
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
Xu MJ; Chu C; Rubin S; Lin LL
Am J Clin Oncol; 2017 Dec; 40(6):598-604. PubMed ID: 26237194
[TBL] [Abstract][Full Text] [Related]
9. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study.
Tewari KS; Filiaci VL; Spirtos NM; Mannel RS; Thigpen JT; Cibull ML; Monk BJ; Randall ME
Gynecol Oncol; 2012 Apr; 125(1):87-93. PubMed ID: 22155678
[TBL] [Abstract][Full Text] [Related]
10. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
[TBL] [Abstract][Full Text] [Related]
11. A multi-institutional analysis of sequential versus 'sandwich' adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma.
Onal C; Sari SY; Yildirim BA; Yavas G; Gultekin M; Guler OC; Akyurek S; Yildiz F
J Gynecol Oncol; 2019 May; 30(3):e28. PubMed ID: 30887753
[TBL] [Abstract][Full Text] [Related]
12. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Garcia-Soto AE; Java JJ; Nieves Neira W; Pearson JM; Cohn DE; Lele SB; Tewari KS; Walker JL; Alvarez Secord A; Armstrong DK; Copeland LJ
Gynecol Oncol; 2016 Dec; 143(3):484-489. PubMed ID: 27726923
[TBL] [Abstract][Full Text] [Related]
13. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.
Darcy KM; Brady WE; McBroom JW; Bell JG; Young RC; McGuire WP; Linnoila RI; Hendricks D; Bonome T; Farley JH;
Gynecol Oncol; 2008 Dec; 111(3):487-95. PubMed ID: 18834621
[TBL] [Abstract][Full Text] [Related]
14. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Rose PG; Java JJ; Morgan MA; Alvarez-Secord A; Kesterson JP; Stehman FB; Warshal DP; Creasman WT; Hanjani P; Morris RT; Copeland LJ
Gynecol Oncol; 2016 Dec; 143(3):511-515. PubMed ID: 27692669
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.
Sun R; Liu Z; Wang L; Lv W; Liu J; Ding C; Yuan Y; Lei G; Xu C
Tumour Biol; 2015 Sep; 36(9):7195-204. PubMed ID: 25894372
[TBL] [Abstract][Full Text] [Related]
17. Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2.
Bishop EA; Java JJ; Moore KN; Walker JL
Int J Gynecol Cancer; 2017 May; 27(4):730-737. PubMed ID: 28399028
[TBL] [Abstract][Full Text] [Related]
18. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix.
Thigpen T; Vance RB; Khansur T
Semin Oncol; 1995 Oct; 22(5 Suppl 12):67-75. PubMed ID: 7481864
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
Fleming GF; Brunetto VL; Cella D; Look KY; Reid GC; Munkarah AR; Kline R; Burger RA; Goodman A; Burks RT
J Clin Oncol; 2004 Jun; 22(11):2159-66. PubMed ID: 15169803
[TBL] [Abstract][Full Text] [Related]
20. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
